BofA lowered the firm’s price target on ResMed to $220 from $230 and keeps a Buy rating on the shares. Following five quarters of sequential growth, BofA expects a 2% revenue drop in fiscal Q1 compared to Q4, reflecting seasonality. The firm believes the market has oversold the shares on GLP-1 concerns, but lowers its price target as it adjusts near-term operating cost expectations higher.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on RMD:
- ResMed price target lowered to $175 from $275 at Oppenheimer
- Target upgraded, Beyond Meat downgraded: Wall Street’s top analyst calls
- RBC downgrades ResMed to Sector Perform amid GLP-1 drug fears
- ResMed downgraded to Sector Perform from Outperform at RBC Capital
- ResMed upgraded to Overweight from Neutral at JPMorgan